Chris Dunne

VP, Finance at Novavax

Mr. Dunne is vice president of finance with responsibility for managing all financial reporting. Prior to joining Novavax as the executive director of finance, he was senior director of finance at Ore Pharmaceuticals (previously known as Gene Logic), a publicly traded biotechnology company, from 1996 until joining Novavax in January 2010. Mr. Dunne’s prior experience included roles as a senior project accountant for Akridge, where he was responsible for the accounting activities of a portfolio of commercial real estate partnerships and corporations located in the Washington, D.C., metropolitan area, and with Deloitte & Touche LLP, where he managed audits for a number of public and private companies, including preparation for initial public offerings and SEC reporting. Mr. Dunne received a bachelor of science degree in business management, accounting from the University of Maryland and is a certified public accountant.
By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.